Obefazimod (ABX464) for moderate-to-severe Crohn’s disease: clinical development of a novel oral therapeutic approach

Expert Opinion on Emerging Drugs 2026

View at publisher
Authors: Sailish Honap, Axel Dignass, Vipul Jairath, Fernando Magro, Silvio Danese, Laurent Peyrin‐Biroulet
DOI: 10.1080/14728214.2026.2693032
Cited by: 1
References: 17

Abstract

1. Therapeutic advances in inflammatory bowel disease have accelerated over the past decade; however, progress has not been uniform across disease subtypes. Crohn’s disease continues to lag behind ...

Fields of Study & Subjects

Inflammatory Bowel Disease Autoimmune and Inflammatory Disorders Celiac Disease Research and Management

Publication details

Journal / source
Expert Opinion on Emerging Drugs
Publisher
Informa UK Limited
Volume
31
Issue
3
Pages
73–77
Publication date
20 June 2026
Language
EN